Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025
Presentation underscores Andarix’s leadership in advancing radiometal-based cancer therapeutics and highlights partnering and investment opportunities in a rapidly growing field.
Boston, MA, United States, 21st Aug 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today announced that Chief Executive Officer Chris Adams will present at the upcoming International Symposium on Bioorganometallic Chemistry (ISBOMC) 2025, taking place August 26–29, 2025, in Paris, France.
Mr. Adams will highlight Andarix’s innovative approach to targeted radiometal-based therapeutics designed to treat lung cancer, focusing on the company’s proprietary delivery platforms that combine the precision of biologically targeted ligands with the therapeutic power of radiometals. The presentation will outline recent preclinical and translational research data underscoring the potential of these agents to address the high unmet medical need in patients with advanced lung cancer.
Presentation Details:
Conference: International Symposium on Bioorganometallic Chemistry (ISBOMC) 2025
Date: August 26–29, 2025
Location: Paris, France
Presenter: Chris Adams, CEO, Andarix Pharmaceuticals
[Insert exact date/time of presentation when available]
“Andarix is committed to advancing targeted radiotherapeutics that deliver highly potent treatments directly to cancer cells, while sparing normal tissues,” said Chris Adams, CEO of Andarix Pharmaceuticals. “We are excited to share our progress with the scientific community at ISBOMC 2025, a leading forum for advancing the field of bioorganometallic chemistry.”
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a biopharmaceutical company pioneering targeted radiotherapeutics for oncology using proprietary radiometal conjugate technology. By combining precision targeting with the proven efficacy of radiotherapy, Andarix is developing a pipeline of novel therapies with the potential to transform outcomes in hard-to-treat cancers.
Contact:
info@andarix.com
617-957-9858
Media Contact
Organization: Andarix Pharmaceuticals
Contact Person: Chris Adams
Website: https://andarix.com
Email: Send Email
Contact Number: +16179579858
Address: 1660 Soldiers Field Rd
City: Boston
State: MA
Country: United States
Release Id: 21082532664